NEW YORK (TheStreet) -- Protalix BioTherapeutics (PLX) surged Thursday after the company co-announced with Pfizer (PFE) that the FDA had approved the expansion of ELELYSO for injection in pediatric patients.
The expansion means the drug is now indicated for long-term enzyme replacement therapy, or ERT, for both adult and pediatric patients who have been diagnosed with Type 1 Gaucher disease.
Type 1 is the most common form of the inherited disease, which causes enlargement of the liver and spleen, anemia, decline in blood platelets leading to bruising, lung disease, and bone problems such as pain, fractures and arthritis.
Must Read: 50 Stocks Hedge Funds LoveSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Protalix was up 13.69% to $2.74 at 2:45 p.m. PLX data by YCharts EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts